Greer Laboratories   Report issue

Contributed to NME For profit Phase 1 Phase 2 Phase 3
Founded: Lenoir NC United States (1904)
Status: Acquired by Stallergenes (2015)

Organization Overview

First Clinical Trial
2008
NCT00599872
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2017

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Greer Laboratories, Inc. | Woodmont Pharmaceuticals, Inc.

Active Ingredients

Drugs in Phase 3 Trials (1)

short ragweed pollen allergen (3 trials)

Drugs in Phase 2 Trials (1)

milk powder (1 trial)

Drugs in Phase 1 Trials (1)

pf-04236921 (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Conjunctivitis (Phase 1)

Conjunctivitis, Allergic (Phase 1)

Hypersensitivity (Phase 2)

Milk Hypersensitivity (Phase 2)

Rhinitis (Phase 3)

Rhinitis, Allergic (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 4
  • # of Trial APIs: 3